MoonLake Immunotherapeutics (MLTX)
45.26
+2.69
(+6.32%)
USD |
NASDAQ |
May 03, 16:00
45.23
-0.03
(-0.07%)
Pre-Market: 20:00
MoonLake Immunotherapeutics Shareholders Equity (Quarterly): 495.68M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 495.68M |
September 30, 2023 | 424.93M |
June 30, 2023 | 489.80M |
March 31, 2023 | 42.00M |
Date | Value |
---|---|
December 31, 2022 | 48.90M |
September 30, 2022 | 55.29M |
June 30, 2022 | 63.51M |
December 31, 2021 | -11.64M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-11.64M
Minimum
Dec 2021
495.68M
Maximum
Dec 2023
201.06M
Average
59.40M
Median
Shareholders Equity (Quarterly) Benchmarks
Qiagen NV | 3.600B |
LENZ Therapeutics Inc | -- |
AC Immune SA | 191.25M |
CRISPR Therapeutics AG | 1.883B |
Addex Therapeutics Ltd | 1.364M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 526.54M |
Total Liabilities (Quarterly) | 13.05M |